OncoWuXi Newsletter: June 2022
WuXi AppTec xenograft and syngeneic tumor models in rats and CD47-related in vitro assay platform
Continue ReadingKnowledge Library
WuXi AppTec Biology Services
WuXi Biology provides a full spectrum of services and solutions to support stand-alone and integrated projects, from target discovery to...
Continue Reading Structure-based optimization of hydroxylactam as potent, cell-active inhibitors of lactate dehydrogenase
Structure-based design was utilized to optimize 6,6-diaryl substituted dihydropyrone and hydroxylactam to obtain inhibitors of lactate dehydrogenase (LDH) with low...
Continue Reading
Brain metastasis mouse models for the evaluation of multikinase inhibitors on ROS1-fusion-positive lung cancer
Lung cancer is the leading cause of cancer-related death worldwide. Nearly 80% of lung cancers are non-small cell lung cancer...
Continue Reading
Intra-carotid artery brain metastasis models for the evaluation of lung and breast cancer drugs
Non-CNS metastatic brain cancer is approximately 10 times more common than CNS cancer. Lung cancer and breast cancer account for...
Continue Reading
Developing drug-induced resistant tumor models for efficacy evaluation of next-generation anticancer therapies
The therapeutic landscape of cancer has been transformed over the last few decades. Our understanding of cancer and its therapeutic...
Continue Reading